Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR

被引:26
|
作者
Schanda, Nicola [1 ]
Sauer, Tim [1 ]
Kunz, Alexander [1 ]
Huckelhoven-Krauss, Angela [1 ]
Neuber, Brigitte [1 ]
Wang, Lei [1 ]
Hinkelbein, Mandy [1 ]
Sedloev, David [1 ]
He, Bailin [1 ]
Schubert, Maria-Luisa [1 ]
Muller-Tidow, Carsten [1 ]
Schmitt, Michael [1 ]
Schmitt, Anita [1 ]
机构
[1] Univ Hosp Heidelberg, Dept Internal Med Hematol Oncol & Rheumatol 5, D-69120 Heidelberg, Germany
关键词
CD19; CAR-T cells; flow cytometry (FACS); polymerase chain reaction (PCR); detection reagent; CAR T-CELLS; ANTIGEN; STRATEGIES; LYMPHOMA; SAFETY;
D O I
10.3390/cells10113208
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Chimeric-antigen-receptor-T (CAR-T) cells are currently revolutionizing the field of cancer immunotherapy. Therefore, there is an urgent need for CAR-T cell monitoring by clinicians to assess cell expansion and persistence in patients. CAR-T cell manufacturers and researchers need to evaluate transduction efficiency and vector copy number for quality control. Here, CAR expression was analyzed in peripheral blood samples from patients and healthy donors by flow cytometry with four commercially available detection reagents and on the gene level by quantitative polymerase chain reaction (qPCR). Flow cytometric analysis of CAR expression showed higher mean CAR expression values for CD19 CAR detection reagent and the F(ab')2 antibody than Protein L and CD19 Protein. In addition, the CD19 CAR detection reagent showed a significantly lower median background staining of 0.02% (range 0.007-0.06%) when compared to the F(ab')2 antibody, CD19 protein and Protein L with 0.80% (range 0.47-1.58%), 0.65% (range 0.25-1.35%) and 0.73% (range 0.44-1.23%). Furthermore, flow cytometry-based CAR-T cell frequencies by CD19 CAR detection reagent showed a good correlation with qPCR results. In conclusion, quality control of CAR-T cell products can be performed by FACS and qPCR. For the monitoring of CAR-T cell frequencies by FACS in patients, CAR detection reagents with a low background staining are preferable.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] CD19 CAR T Cells
    Sadelain, Michael
    CELL, 2017, 171 (07) : 1471 - 1471
  • [42] RAPID GENERATION OF CMV-SPECIFIC CD19 CAR T CELLS: PROTOCOL OPTIMIZATION AND CMV-CD19 CAR T CELL CHARACTERIZATION
    Lamb, M.
    Thakkar, A.
    Lee, D. A.
    CYTOTHERAPY, 2023, 25 (06) : S235 - S235
  • [43] A safe and potent anti-CD19 CAR T cell therapy
    Zhitao Ying
    Xue F. Huang
    Xiaoyu Xiang
    Yanling Liu
    Xi Kang
    Yuqin Song
    Xiaokai Guo
    Hanzhi Liu
    Ning Ding
    Tingting Zhang
    Panpan Duan
    Yufu Lin
    Wen Zheng
    Xiaopei Wang
    Ningjing Lin
    Meifeng Tu
    Yan Xie
    Chen Zhang
    Weiping Liu
    Lijuan Deng
    Shunyu Gao
    Lingyan Ping
    Xuejuan Wang
    Nina Zhou
    Junqing Zhang
    Yulong Wang
    Songfeng Lin
    Mierzhati Mamuti
    Xueyun Yu
    Lizhu Fang
    Shuai Wang
    Haifeng Song
    Guan Wang
    Lindsey Jones
    Jun Zhu
    Si-Yi Chen
    Nature Medicine, 2019, 25 : 947 - 953
  • [44] Understanding Outcomes of CD19-Targeted CAR T Cell Immunotherapy
    Turtle, Cameron J.
    BLOOD, 2017, 130
  • [45] Predictors of Response to CD19-Specific CAR T Cell Therapy
    Melenhorst, Jan J.
    Fraietta, Joseph A.
    Lacey, Simon F.
    Orlando, Elena J.
    Ambrose, David E.
    Hwang, Wei-Ting
    Wilcox, Nicholas
    Bedoya, Felipe
    Dorfmeier, Corin
    Chen, Fang
    Parakandi, Harit
    Gupta, Minnal
    Pequignot, Edward
    Johnson, F. Brad
    Kulikovskaya, Irina
    Liu, Li
    Lundh, Stefan
    Wang, Yan
    Xu, Jun
    Young, Regina M.
    Levine, Bruce L.
    Frey, Noelle V.
    Siegel, Donald L.
    Huang, Alexander C.
    Wherry, E. John
    Khassim, Sadik H.
    Pruteanu-Malinici, Iulian
    Brogdon, Jennifer L.
    Bitter, Hans
    Porter, David L.
    June, Carl H.
    MOLECULAR THERAPY, 2017, 25 (05) : 238 - 238
  • [46] A second CD19 CAR T-cell infusion: yes or no?
    Casucci, Monica
    Ciceri, Fabio
    BLOOD, 2021, 137 (03) : 284 - 286
  • [47] A safe and potent anti-CD19 CAR T cell therapy
    Ying, Zhitao
    Huang, Xue F.
    Xiang, Xiaoyu
    Liu, Yanling
    Kang, Xi
    Song, Yuqin
    Guo, Xiaokai
    Liu, Hanzhi
    Ding, Ning
    Zhang, Tingting
    Duan, Panpan
    Lin, Yufu
    Zheng, Wen
    Wang, Xiaopei
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Zhang, Chen
    Liu, Weiping
    Deng, Lijuan
    Gao, Shunyu
    Ping, Lingyan
    Wang, Xuejuan
    Zhou, Nina
    Zhang, Junqing
    Wang, Yulong
    Lin, Songfeng
    Mamuti, Mierzhati
    Yu, Xueyun
    Fang, Lizhu
    Wang, Shuai
    Song, Haifeng
    Wang, Guan
    Jones, Lindsey
    Zhu, Jun
    Chen, Si-Yi
    NATURE MEDICINE, 2019, 25 (06) : 947 - +
  • [48] Complications after CD19+CAR T-Cell Therapy
    Penack, Olaf
    Koenecke, Christian
    CANCERS, 2020, 12 (11) : 1 - 17
  • [49] SENSITIVITY AND SPECIFICITY OF FLOW-CYTOMETRY IN THE DIAGNOSIS OF COLONIC-CARCINOMA
    MCKINLEY, M
    BRONZO, R
    WEISSMAN, G
    GRUENEBERG, D
    KAHN, E
    BUDMAN, D
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1984, 79 (10): : 823 - 824
  • [50] New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry
    Maryamchik, Elena
    Gallagher, Kathleen Mary Ellen
    Preffer, Frederic I.
    Kadauke, Stephan
    Maus, Marcela V.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2020, 98 (04) : 299 - 327